SCHEMBL14873229

SCHEMBL14873229

CNC(=O)CC(=O)NC1CCNCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 5/20 0.55
GNAI3 P08754 1/20 0.54
GNAO1 P09471 1/20 0.54
GNAI1 P63096 1/20 0.54
POLB P06746 1/20 0.50
CHRM3 P20309 2/20 0.44
CHRM5 P08912 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
EPHX2 P34913 1/20 0.40
SMYD3 Q9H7B4 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
CHRM1 P11229 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14873231 0.89 KCNH2 (0.44) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL14873284 0.86 SMN1; SMN2 (0.45) EPHX1EPHX2SMN1; SMN2NPSR1HPGD
SCHEMBL27224567 0.82 EPHX1 (0.57) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL14873283 0.82 SMN1; SMN2 (0.52) EPHX1EPHX2SMN1; SMN2NPSR1HPGD
SCHEMBL617591 0.80 GNAI3 (0.62) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL14873215 0.80 NPSR1 (0.58) EPHX1EPHX2SMN1; SMN2NPSR1HPGD
SCHEMBL13927599 0.78 EPHX1 (0.57) EPHX1GNAI3GNAO1GNAI1POLB
Hydrochloric Acid SCHEMBL6163168 0.78 GNAI3 (0.65) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL5106542 0.78 EPHX1 (0.61) EPHX1GNAI3GNAO1GNAI1POLB
SCHEMBL5214633 0.78 EPHX1 (0.75) EPHX1GNAI3GNAO1GNAI1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183254-B1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC (CA) 2017-06-21 EP disclosed
US-9018378-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2015-04-28 US disclosed
US-8906852-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-8907091-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-8846927-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-09-30 US disclosed
US-8569503-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2013-10-29 US disclosed
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2013-06-27 US disclosed
US-20130096088-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET EPHX1 2705/4885GNAI3 462/4885GNAO1 1398/4885
US-20130096088-A1 Inhibitors of Protein Tyrosine Kinase Activity KDR, FLT1, FLT4 EPHX1 3059/4885GNAI3 546/4885GNAO1 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.